

RESOURCES

PEOPLE

Following the decision of **Paul Bevan** to stand down from his position as research director, therapeutics, Xenova Group (Slough, UK) has announced the appointment of **John Waterfall** as R&D director. Dr. Waterfall joins Xenova from Hoffmann-La Roche, where he was divisional vice president, global project management. Dr. Bevan will remain as a nonexecutive board member. In addition, the company announced the appointment of **Michael Moore**, formerly head of Xenova's discovery division, as chief scientific officer.

GalaGen (Arden Hills, MN) has announced the appointment of **Austen S. Cargill II** to its board of directors. Dr. Cargill currently serves on the board and as corporate vice president and director of R&D worldwide for Cargill, Inc. He replaces **David R. Spreng**, a director since 1993. GalaGen has also named **Rhonda S. Witwer** director of business development. Ms. Witwer was previously manager of business development at Monsanto.

Karin Eastham has been named senior vice president and CFO of Diversa (San Diego, CA). She was most recently vice president of finance and administration and CFO of CombiChem.



Sequenom (San Diego, CA) has named **Delbert F. Foit, Jr.**, chief operating officer. Mr. Foit comes to Sequenom after serving as vice president of North American operations of Boehringer Mannheim's laboratory systems division.

JRH Biosciences (Lenexa, KS) has named **Thomas G. Giarla** president, replacing **Paul Bordonaro**, who will take on the new position of president, biosciences, of JRH's parent company, CSL Limited. Mr. Giarla has been director of operations for JRH Biosciences during the last five years.

Denise Gilbert has retired as executive vice president and CFO of Incyte Pharmaceuticals (Palo Alto, CA), a position she has held since 1995. **Lee Bendekgey**, Incyte's general counsel, will serve as interim CFO until a replacement is found. Dr. Gilbert is leaving Incyte to pursue a unique opportunity to bicycle around the world during the year 2000. She will spend the summer bicycling across the US in preparation for her trip, and will return in August to serve in an advisory capacity through the end of the year.

Inhale Therapeutic Systems (San Carlos, CA) has appointed **Irwin Lerner** to its board of directors, and has announced that **Terry Opdendyk** is retiring from the board after eight years as chairman. Inhale's two co-CEOs, Robert Chess and Ajit Gill, will expand their titles, with Chess becoming chairman and co-CEO and Gill becoming president and co-CEO. Mr. Lerner is the retired chairman of the board and executive committee, president, and CEO of Hoffmann-La Roche, where he had a 32-year career. In addition, he served for 12 years on the board of the Pharmaceutical Manufacturers Association, where he initiated and chaired the FDA Issues Committee.

Sugen (South San Francisco, CA) has announced the appointments of **Gerald H. Moeller** and **Samuel Hamad** to its board of directors. Dr. Moeller was previously president and CEO of the Boehringer Mannheim Group. Following Boehringer Mannheim's acquisition by Hoffmann-La Roche in 1998, Dr. Moeller served as head of strategic marketing and global development for Roche Pharma and a member of the executive committee of Hoffmann-La Roche. Mr. Hamad has held various senior management positions with Bristol-Myers Squibb Company, including president of Bristol-Myers Squibb Europe and president, Bristol-Myers Squibb Intercontinental.

Matthew J. Pfeffer has been elected to the position of vice president and CFO of Cell Genesys (Foster City, CA). Mr. Pfeffer was previously director of finance at Cell Genesys, and has served as acting CFO since September 1998.

Sibia Neurosciences (La Jolla, CA) has named **Carla M. Suto** vice president, HTS and technology development. Dr. Suto joined Sibia as director of HTS in 1996. Before that, she held the position of group leader in the department of pharmacology and drug discovery at Signal Pharmaceuticals.

Gerald F. Vovis has joined Genaissance Pharmaceuticals (New Haven, CT) as senior vice president for genomics. He most recently held the position of senior vice president, scientific affairs, at Genome Therapeutics.

Xenogen (Alameda, CA) has announced that **Raymond J. Whitaker** has joined its board, in association with an \$11 million equity financing. Dr. Whitaker is vice president of S.R. One Ltd., the venture capital arm of SmithKline Beecham (London), one of the participants in the financing round.